Novel factors interfering with human immunodeficiency virus-type 1 replication in vivo and in vitro

Tissue Antigens

Volumn 81, Issue 2, 2013, Pages 61-71

  Vicenzi, E ^a   Poli, G ^a,b,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c P2 P3 Laboratories   (Italy)

Author keywords

Epigenetics; Eradication; Human immunodeficiency virus; Human immunodeficiency virus cure; Restriction factors; STAT5; Transcription; TRIM22

Indexed keywords

NEF PROTEIN; STAT5 PROTEIN; TRIM22 PROTEIN; UNCLASSIFIED DRUG; VIF PROTEIN; VIRUS PROTEIN; VPR PROTEIN; VPU PROTEIN; VPX PROTEIN;

EPIGENETICS; GENE DELETION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; TRANSCRIPTION REGULATION; VIRION; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS EXPRESSION; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

HIV INFECTIONS; HIV-1; HOST-DERIVED CELLULAR FACTORS; HOST-PATHOGEN INTERACTIONS; HUMANS; T-LYMPHOCYTES; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; PRIMATES;

EID: 84872672203     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12047     Document Type: Review

References (92)

1. Berger EA, Doms RW, Fenyo EM et al. A new classification for HIV-1 [letter]. Nature 1998: 391: 240.
2. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators [see comments]. N Engl J Med 1998: 338: 853-60.
3. Deeks SG, Autran B, Berkhout B et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012: 12: 607-14.
4. Laguette N, Bregnard C, Benichou S, Basmaciogullari S. Human immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency virus Nef proteins. Mol Aspects Med 2010: 31: 418-33.
5. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992: 258: 1938-41.
6. Learmont J, Tindall B, Evans L et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor [see comments]. Lancet 1992: 340: 863-7.
7. Baba TW, Jeong YS, Pennick D, Bronson R, Greene MF, Ruprecht RM. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995: 267: 1820-5.
8. Greenway AL, McPhee DA, Grgacic E et al. Nef 27, but not the Nef 25 isoform of human immunodeficiency virus-type 1 pNL4.3 down-regulates surface CD4 and IL-2R expression in peripheral blood mononuclear cells and transformed T cells. Virology 1994: 198: 245-56.
9. Schwartz O, Marechal V, Le Gall S, Lemonnier F, Heard JM. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996: 2: 338-42.
10. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002: 418: 646-50.
11. Goila-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008: 5: 51.
12. Peng G, Greenwell-Wild T, Nares S et al. Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression. Blood 2007: 110: 393-400.
13. Strebel K, Klimkait T, Martin MA. A novel gene of HIV-1, vpu, and its 16-kilodalton product. Science 1988: 241: 1221-3.
14. Dube M, Bego MG, Paquay C, Cohen EA. Modulation of HIV-1-host interaction: role of the Vpu accessory protein. Retrovirology 2010: 7: 114.
15. Andrew A, Strebel K. HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Mol Aspects Med 2010: 31: 407-17.
16. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J Biol Chem 1995: 270: 25564-9.
17. Subbramanian RA, Kessous-Elbaz A, Lodge R et al. Human immunodeficiency virus type 1 Vpr is a positive regulator of viral transcription and infectivity in primary human macrophages. J Exp Med 1998: 187: 1103-11.
18. Popov S, Rexach M, Ratner L, Blobel G, Bukrinsky M. Viral protein R regulates docking of the HIV-1 preintegration complex to the nuclear pore complex. J Biol Chem 1998: 273: 13347-52.
19. Andersen JL, Le Rouzic E, Planelles V. HIV-1 Vpr: mechanisms of G2 arrest and apoptosis. Exp Mol Pathol 2008: 85: 2-10.
20. Refaeli Y, Levy DN, Weiner DB. The glucocorticoid receptor type II complex is a target of the HIV-1 vpr gene product. Proc Natl Acad Sci U S A 1995: 92: 3621-5.
21. Yu XF, Yu QC, Essex M, Lee TH. The vpx gene of simian immunodeficiency virus facilitates efficient viral replication in fresh lymphocytes and macrophage. J Virol 1991: 65: 5088-91.
22. Laguette N, Sobhian B, Casartelli N et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature 2011: 474: 654-7.
23. Hrecka K, Hao C, Gierszewska M et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature 2011: 474: 658-61.
24. Lahouassa H, Daddacha W, Hofmann H et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol 2012: 13: 223-8.
25. Laguette N, Rahm N, Sobhian B et al. Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe 2012: 11: 205-17.
26. Zhan P, Liu X, De Clercq E. Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. Curr Med Chem 2010: 17: 495-503.
27. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002: 110: 521-9.
28. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 2010: 11: 1005-13.
29. Vazquez N, Greenwell-Wild T, Marinos NJ et al. Human immunodeficiency virus type 1-induced macrophage gene expression includes the p21 gene, a target for viral regulation. J Virol 2005: 79: 4479-91.
30. Zhang J, Scadden DT, Crumpacker CS. Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest 2007: 117: 473-81.
31. Wu W, Kehn-Hall K, Pedati C et al. Drug 9AA reactivates p21/Waf1 and Inhibits HIV-1 progeny formation. Virol J 2008: 5: 41.
32. Bergamaschi A, David A, Le Rouzic E, Nisole S, Barre-Sinoussi F, Pancino G. The CDK inhibitor p21Cip1/WAF1 is induced by FcgammaR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J Virol 2009: 83: 12253-65.
33. + T cells from HIV controllers. Blood 2011: 118: 955-64.
34. + T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J Clin Invest 2011: 121: 1549-60.
35. Jacque JM, Stevenson M. The inner-nuclear-envelope protein emerin regulates HIV-1 infectivity. Nature 2006: 441: 641-5.
36. Christ F, Voet A, Marchand A et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 2010: 6: 442-8.
37. Christ F, Thys W, De Rijck J et al. Transportin-SR2 imports HIV into the nucleus. Curr Biol 2008: 18: 1192-202.
38. + T lymphocytes. Nat Med 2010: 16: 329-33.
39. Allouch A, Di Primio C, Alpi E et al. The TRIM family protein KAP1 inhibits HIV-1 integration. Cell Host Microbe 2011: 9: 484-95.
40. Mbonye U, Karn J. Control of HIV latency by epigenetic and non-epigenetic mechanisms. Curr HIV Res 2011: 9: 554-67.
41. Garcia JA, Wu FK, Mitsuyasu R, Gaynor RB. Interactions of cellular proteins involved in the transcriptional regulation of the human immunodeficiency virus. EMBO J 1987: 6: 3761-70.
42. Poli G. Laureate ESCI award for excellence in clinical science 1999. Cytokines and the human immunodeficiency virus: from bench to bedside. European Society for Clinical Investigation. Eur J Clin Invest 1999: 29: 723-32.
43. O'Shea JJ, Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012: 36: 542-50.
44. Bovolenta C, Camorali L, Lorini AL et al. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 1999: 94: 4202-9.
45. Crotti A, Lusic M, Lupo R et al. Naturally occurring C-terminally truncated STAT5 is a negative regulator of HIV-1 expression. Blood 2007: 109: 5380-9.
46. Selliah N, Zhang M, DeSimone D et al. The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells. Virology 2006: 344: 283-91.
47. Della Chiara G, Crotti A, Liboi E, Giacca M, Poli G, Lusic M. Negative regulation of HIV-1 transcription by a heterodimeric NF-κB1/p50 and C-terminally truncated STAT5 complex. J Mol Biol 2011: 410: 933-43.
48. Ramos HL, O'Shea JJ, Watford WT. STAT5 isoforms: controversies and clarifications. Biochem J 2007: 404: e1-2.
49. Bovolenta C, Camorali L, Lorini AL et al. In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/Late simian virus 40 factor. J Immunol 1999: 163: 6892-7.
50. Boudinot P, van der Aa LM, Jouneau L et al. Origin and evolution of TRIM proteins: new insights from the complete TRIM repertoire of zebrafish and pufferfish. PLoS One 2011: 6: e22022.
51. Sawyer SL, Emerman M, Malik HS. Discordant evolution of the adjacent antiretroviral genes TRIM22 and TRIM5 in mammals. PLoS Pathog 2007: 3: e197.
52. Kajaste-Rudnitski A, Pultrone C, Marzetta F, Ghezzi S, Coradin T, Vicenzi E. Restriction factors of retroviral replication: the example of Tripartite Motif (TRIM) protein 5 alpha and 22. Amino Acids 2010: 39: 1-9.
53. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 2004: 427: 848-53.
54. Towers GJ. The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 2007: 4: 40.
55. Tissot C, Mechti N. Molecular cloning of a new interferon-induced factor that represses human immunodeficiency virus type 1 long terminal repeat expression. J Biol Chem 1995: 270: 14891-8.
56. Bouazzaoui A, Kreutz M, Eisert V et al. Stimulated trans-acting factor of 50 kDa (Staf50) inhibits HIV-1 replication in human monocyte-derived macrophages. Virology 2006: 356: 79-94.
57. Kajaste-Rudnitski A, Marelli SS, Pultrone C et al. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol 2011: 85: 5183-96.
58. Barr SD, Smiley JR, Bushman FD. The interferon response inhibits HIV particle production by induction of TRIM22. PLoS Pathog 2008: 4: e1000007.
59. Franzoso G, Biswas P, Poli G et al. A family of serine proteases expressed exclusively in myelo-monocytic cells specifically processes the nuclear factor-kappa B subunit p65 in vitro and may impair human immunodeficiency virus replication in these cells. J Exp Med 1994: 180: 1445-56.
60. Gao M, Karin M. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol Cell 2005: 19: 581-93.
61. Gao B, Duan Z, Xu W, Xiong S. Tripartite motif-containing 22 inhibits the activity of hepatitis B virus core promoter, which is dependent on nuclear-located RING domain. Hepatology 2009: 50: 424-33.
62. Eldin P, Papon L, Oteiza A, Brocchi E, Lawson TG, Mechti N. TRIM22 E3 ubiquitin ligase activity is required to mediate antiviral activity against encephalomyocarditis virus. J Gen Virol 2009: 90: 536-45.
63. Hakre S, Chavez L, Shirakawa K, Verdin E. Epigenetic regulation of HIV latency. Curr Opin HIV AIDS 2011: 6: 19-24.
64. Kim HG, Kim KC, Roh TY et al. Gene silencing in HIV-1 latency by polycomb repressive group. Virol J 2011: 8: 179.
65. Friedman J, Cho WK, Chu CK et al. Epigenetic silencing of HIV-1 by the histone H3 lysine 27 methyltransferase enhancer of Zeste 2. J Virol 2011: 85: 9078-89.
66. + T cells from infected individuals receiving antiretroviral therapy. J Virol 2012: 86: 5390-2.
67. Rohr O, Lecestre D, Chasserot-Golaz S et al. Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells. J Virol 2003: 77: 5415-27.
68. Cherrier T, Suzanne S, Redel L et al. p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 2009: 28: 3380-9.
69. Le Douce V, Colin L, Redel L et al. LSD1 cooperates with CTIP2 to promote HIV-1 transcriptional silencing. Nucleic Acids Res 2012: 40: 1904-15.
70. Archin NM, Liberty AL, Kashuba AD et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012: 487: 482-5.
71. Shan L, Deng K, Shroff NS et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012: 36: 491-501.
72. Palmisano I, Della Chiara G, D'Ambrosio RL et al. Amino acid starvation induces reactivation of silenced transgenes and latent HIV-1 provirus via down-regulation of histone deacetylase 4 (HDAC4). Proc Natl Acad Sci U S A 2012: 109: E2284-93.
73. Savarino A, Mai A, Norelli S et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009: 6: 52.
74. Weiss ER, Gottlinger H. The role of cellular factors in promoting HIV budding. J Mol Biol 2011: 410: 525-33.
75. Gottlinger HG, Dorfman T, Sodroski JG, Haseltine WA. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A 1991: 88: 3195-9.
76. Garrus JE, von Schwedler UK, Pornillos OW et al. Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding. Cell 2001: 107: 55-65.
77. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 1989: 244: 575-7.
78. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008: 451: 425-30.
79. Le Tortorec A, Willey S, Neil SJ. Antiviral inhibition of enveloped virus release by tetherin/BST-2: action and counteraction. Viruses 2011: 3: 520-40.
80. Andrew AJ, Miyagi E, Strebel K. Differential effects of human immunodeficiency virus type 1 Vpu on the stability of BST-2/tetherin. J Virol 2011: 85: 2611-9.
81. Orenstein JM, Jannotta F. Human immunodeficiency virus and papovavirus infections in acquired immunodeficiency syndrome: an ultrastructural study of three cases. Hum Pathol 1988: 19: 350-61.
82. Biswas P, Poli G, Kinter AL et al. Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells. J Exp Med 1992: 176: 739-50.
83. Pelchen-Matthews A, Kramer B, Marsh M. Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 2003: 162: 443-55.
84. Ono A, Freed EO. Cell-type-dependent targeting of human immunodeficiency virus type 1 assembly to the plasma membrane and the multivesicular body. J Virol 2004: 78: 1552-63.
85. Deneka M, Pelchen-Matthews A, Byland R, Ruiz-Mateos E, Marsh M. In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. J Cell Biol 2007: 177: 329-41.
86. Cassol E, Cassetta L, Alfano M, Poli G. Macrophage polarization and HIV-1 infection. J Leukocyte Biol 2010: 87: 599-608.
87. Berger G, Durand S, Fargier G et al. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 2011: 7: e1002221.
88. Koning FA, Goujon C, Bauby H, Malim MH. Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol 2011: 85: 13448-52.
89. Levy Y, Sereti I, Tambussi G et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012: 55: 291-300.
90. Hutter G, Thiel E. Allogeneic transplantation of CCR5-deficient progenitor cells in a patient with HIV infection: an update after 3 years and the search for patient no. 2. AIDS 2011: 25: 273-4.
91. Sheehy AM, Gaddis NC, Malim MH. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003: 9: 1404-7.
92. Dube M, Roy BB, Guiot-Guillain P, et al. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog 2010: 6: e1000856.